Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 9 | BMC Cancer

Fig. 9

From: ADORA2B promotes proliferation and migration in head and neck squamous cell carcinoma and is associated with immune infiltration

Fig. 9

Correlation between ADORA2B expression and immunotherapy response. Violin plots comparing the expression levels of immune checkpoint molecules between high- and low-ADORA2B expression groups in HNSC patients (a). Kaplan-Meier survival analysis of patients from the IMvigor210 cohort (GSE145281) stratified by ADORA2B expression, showing improved survival outcomes in the low-ADORA2B expression group following ICB therapy (b). Violin plot comparing ADORA2B expression levels between patients with CR/PR and those with SD/PD after ICB treatment (c). Abbreviations: HNSC, head and neck squamous cell carcinoma; ICB, immune checkpoint blockade; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease. Statistical significance: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ns: not significant

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us